These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Based on your analysis of the benefits and costs of routine donor screening for ALT-GPT to reduce the incidence of post-transfusion non-A, non-B hepatitis in your blood services region, what action would you recommend on this matter? Vox Sang; 1983; 44(1):48-64. PubMed ID: 6402857 [No Abstract] [Full Text] [Related]
7. [Currently available means for the prevention of post-transfusion hepatitis and criteria for their application]. Bedarida G, Cambiè G, D'Agostino F, Sterza G. Ric Clin Lab; 1984; 14 Suppl 1():37-60. PubMed ID: 6429830 [No Abstract] [Full Text] [Related]
12. Post-transfusion viral hepatitis and the TTVS. Holland PV, Bancroft W, Zimmerman H. N Engl J Med; 1981 Apr 23; 304(17):1033-5. PubMed ID: 6782483 [No Abstract] [Full Text] [Related]
13. [Prevention of post-transfusion hepatitis non-A, non-B. Report established by the National Agency for the Development of Medical Evaluation on demand of the General Health Direction]. Gayno S. Gastroenterol Clin Biol; 1991 Apr 23; 15(8-9):667-8. PubMed ID: 1752387 [No Abstract] [Full Text] [Related]
14. Transfusion-transmitted hepatitis virus infection. Dodd RY. Hematol Oncol Clin North Am; 1995 Feb 23; 9(1):137-54. PubMed ID: 7737938 [Abstract] [Full Text] [Related]
16. [Hepatitis C and ALT in blood donors]. García Bueno MJ. Sangre (Barc); 1991 Jun 23; 36(3):252-3. PubMed ID: 1948551 [No Abstract] [Full Text] [Related]